No interest in ANP

I have been a SH in ANP for years now and scratch my head wondering why the SP is languishing where it is
even though The Phase 2 1103 was a success and yet no partnering deals forth coming.
So why are we at this crossroad ?
In my opinion I believe that the Phase 2

ATL1103 for Acromegaly results​

didn't set the world on fire  so we need a higher dosage trial at the end of the year.

ANP need to show the higher dosage reduces patient’s baseline serum IGF-I greater than the average reduction  shown in the last trial and Big pharma will show interest.

All patients demonstrated lower sIGF-I levels from baseline at week 14, with an average reduction of 26%.
Greater reductions were observed in patients with lower body weights - up to 36% for the group that received 5.5 mg per kilogram per week.
- See more at: http://lifescientist.com.au/content...-in-acromegaly-786640434#sthash.PiEi5FOq.dpuf

The market is fully aware of our recent results with Phase 2 but the kicker will be the higher dosage outcome and
if successful a partnering deal there after IMO.

Until then we wait and wait hoping something happens in regard to a partnering deal but I don't have high hopes of that happening until the higher dosage is completed.